Discovery Laboratories Inc. (NASDAQ:WINT) shares were up 13.7% on Thursday . The company traded as high as $2.69 and last traded at $2.65, with a volume of 72,328 shares changing hands. The stock had previously closed at $2.33.

A number of research analysts have recently weighed in on WINT shares. HC Wainwright started coverage on Discovery Laboratories in a report on Friday, April 22nd. They issued a “buy” rating and a $8.00 target price on the stock. Zacks Investment Research upgraded Discovery Laboratories from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Thursday, June 23rd.

The company’s market cap is $22.02 million. The firm’s 50-day moving average price is $1.99 and its 200-day moving average price is $2.19.

Discovery Laboratories (NASDAQ:WINT) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.35. Equities research analysts forecast that Discovery Laboratories Inc. will post ($5.87) EPS for the current fiscal year.

Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.